Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyBCBS-Nevada Adult Growth Hormone Prior Auth | Open…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - NevadaPolicy N/A

    Adult Growth Hormone Therapy — Prior Authorization (Somatropin, Skytrofa, Sogroya)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Nevada policy alerts

    Know when Blue Cross Blue Shield - Nevada releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization form and requirements for initiation and reauthorization of somatropin and long-acting growth hormone products for adults (≥18 years), including transition from pediatric therapy and HIV-associated wasting, for members served by Anthem/Blue Cross Blue Shield plans in Indiana.

    Policy Summary
    PayerBlue Cross Blue Shield - Nevada
    PolicyAdult Growth Hormone Therapy — Prior Authorization (Somatropin, Skytrofa, Sogroya)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed prior authorization form with required documentation (biochemical confirmation or applicable testing) or the request will be returned.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥18age requirement for adult therapy
    1 monthoff-therapy interval (pediatric→adult)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >10% WLHIV-associated wasting threshold
    DEXA/BIAlean body mass measurement

    Coverage Criteria

    Transition from pediatric growth hormone therapy

    Covered when ALL of the following are met

    Transition from pediatric GH criteria: The member has reached adult height.

    from SOMATROPIN AGENTS - initial authorization

    Transition from pediatric GH criteria: Member stopped growth hormone therapy for at least one month before reevaluation of the need for continued therapy.at least 1 month

    from SOMATROPIN AGENTS - initial authorization

    Transition from pediatric GH criteria: The prescriber has determined that the member will experience growth hormone deficiency into adulthood and would receive clinical benefit from continued growth hormone therapy.

    from SOMATROPIN AGENTS - initial authorization

    Adult growth hormone deficiency — initiation and monitoring

    Covered when ALL of the following are met

    Adult GH deficiency diagnosis: Diagnosis of adult growth hormone deficiency with biochemical evidence or other applicable testing supporting the diagnosis; member is 18 years of age or older.

    applies to somatropin, Skytrofa, Sogroya

    Intracranial lesion/tumor assessment: Prescriber attests that necessary testing has been performed to ensure there are no expanding intracranial lesions or tumors prior to initiating growth hormone therapy; for reauthorization, prescriber attests to continued monitoring for intracranial tumor recurrence or progression as appropriate.

    applies to all indications

    Skytrofa (lonapegsomatropin) initial authorization

    Covered when ALL of the following are met

    Skytrofa initial: Diagnosis of growth failure due to growth hormone deficiency with biochemical evidence; member is 18 years of age or older; trial and failure of at least ONE preferred somatropin product or medical justification for not using preferred agents.

    SKYTROFA (LONAPEGSOMATROPIN-TCGD) - Initial Authorization

    Intracranial lesion/tumor assessment: Provider attests that they have performed all necessary testing to ensure there are no expanding intracranial lesions or tumors prior to initiating growth hormone therapy.

    SKYTROFA (LONAPEGSOMATROPIN-TCGD) - Initial Authorization

    Sogroya (somapacitan) initial authorization

    Covered when ALL of the following are met

    Sogroya initial: Diagnosis of adult growth hormone deficiency with biochemical evidence; member is 18 years of age or older; trial and failure of Skytrofa (lonapegsomatropin) OR prescriber provides medical justification to use Sogroya instead.

    SOGROYA (SOMAPACITAN) - Initial Authorization

    Intracranial lesion/tumor assessment: Prescriber attests that they have performed all necessary testing to ensure there are no expanding intracranial lesions or tumors prior to initiating growth hormone therapy.

    SOGROYA (SOMAPACITAN) - Initial Authorization

    HIV-associated wasting / cachexia

    Covered when ALL of the following are met

    HIV-associated wasting initial: Diagnosis of HIV-associated wasting or cachexia (Serostim only); quantitative measurement of lean body mass using DEXA or BIA; documentation of involuntary weight loss of >10% of baseline total body weight OR body cell mass <30% for initial approval; member has tried and failed at least one listed alternative (dronabinol, megestrol, anabolic steroids) unless none attempted or other reason provided.>10% weight loss; body cell mass <30%

    SOMATROPIN AGENTS - initial authorization

    HIV-associated wasting continuation: For continuation, the member has demonstrated an increase in total body weight or lean body mass from treatment baseline (documentation required).

    SOMATROPIN AGENTS - reauthorization

    The prior authorization form specifies that the diagnosis of HIV-associated wasting or cachexia is limited to Serostim for this indication. Other somatropin products are not implied to be indicated for HIV-associated wasting unless the prescriber documents a product-specific indication or medical justification on the form.

    For requests involving HIV-associated wasting, the form requires quantitative measurement of lean body mass (using DEXA or BIA) and documentation of either involuntary weight loss >10% of baseline total body weight or body cell mass <30% for initial approval. The prescriber must also document trials of listed alternatives (dronabinol, megestrol, anabolic steroids) or explain why none were tried.

    Coding & Thresholds

    Involuntary weight loss threshold
    Involuntary weight loss threshold>10% of baseline total body weight
    Measurement timingDocument involuntary weight loss relative to member's baseline total body weight
    Applies toInitial approval for HIV-associated wasting or cachexia (Serostim only)
    Body cell mass threshold
    Body cell mass threshold<30% for initial approval
    Use caseAlternative criterion to >10% involuntary weight loss for HIV-associated wasting
    Documentation requirement

    Provider Actions & Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for initiation and reauthorization of adult growth hormone (somatropin) products, including Skytrofa and Sogroya. Transition rules apply for members moving from pediatric therapy to adult therapy; ensure prior authorization is obtained before continued treatment.

    • Prior authorization required for initiation and reauthorization of somatropin agents (including Skytrofa and Sogroya)
    • Transition rules apply for members transitioning from pediatric growth hormone therapy
    Prior Authorization

    Skytrofa - Product-specific Initial Authorization Requirements

    Skytrofa (lonapegsomatropin) initial authorization requires documentation of adult growth hormone deficiency, that the member is 18 years or older, and trial and failure of at least one preferred somatropin product (supported by claims history or chart documentation). If no prior trial, provide medical justification explaining why preferred agents are unsuitable.

    • Member is 18 years of age or older
    • Trial and failure of at least ONE preferred somatropin product (provide chart documentation or dates of use)

    Background

    This form is intended to support clinical assessment and documentation for adult patients with growth hormone deficiency, including those transitioning from pediatric therapy and those with HIV-associated wasting. It guides the prescriber to provide biochemical evidence or other applicable testing to confirm adult growth hormone deficiency and to attest that necessary evaluation for intracranial lesions or tumors has been performed prior to initiating therapy.

    The form also captures key treatment-planning information such as whether the request is for a preferred versus non-preferred agent, product-specific indications or medical justification for non-preferred use, and dosing regimen details needed for the prior authorization review.

    Definitions

    Transition from pediatric growth hormone therapy — definition
    DefinitionMember has reached adult height
    Off-therapy requirementMember stopped growth hormone therapy for at least one month before reevaluation
    Prescriber determinationPrescriber determines the member will have GH deficiency into adulthood and would receive clinical benefit from continued therapy
    HIV-associated wasting — definition
    Required measurement methodsQuantitative lean body mass measurement using DEXA or BIA
    Involuntary weight loss criterion>10% of baseline total body weight
    Alternative criterion
    Policy Summary
    PayerBlue Cross Blue Shield - Nevada
    PolicyAdult Growth Hormone Therapy — Prior Authorization (Somatropin, Skytrofa, Sogroya)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed prior authorization form with required documentation (biochemical confirmation or applicable testing) or the request will be returned.
    SourceLink
    On This Page
    Coverage CriteriaCoding & ThresholdsProvider Actions & RequirementsBackgroundDefinitions
    Must be documented for initial approval of HIV-associated wasting
    Off-therapy interval after pediatric GH
    Minimum off-therapy intervalAt least 1 month off growth hormone therapy before reevaluation
    PurposeEnsures appropriate reassessment before considering transition to adult GH therapy
    Applies toMembers transitioning from pediatric growth hormone therapy
  1. If no trial, provide medical justification for why preferred agent(s) are unsuitable
  2. Provider attestation that necessary testing has been performed to exclude expanding intracranial lesions or tumors prior to initiating therapy
  3. Prior Authorization

    Sogroya - Product-specific Initial Authorization Requirements

    Sogroya (somapacitan) initial authorization requires documentation of adult growth hormone deficiency and that the member is 18 years of age or older. If requesting Sogroya instead of Skytrofa, documentation of trial and failure of Skytrofa (claims or chart) is requested or medical justification for using Sogroya over Skytrofa must be provided.

    • Diagnosis of adult growth hormone deficiency requires biochemical evidence or other applicable testing
    • Member is 18 years of age or older
    • Trial and failure of Skytrofa (supported by claims history or chart documentation) OR documented medical justification for using Sogroya over Skytrofa
    • Provider attestation that necessary testing has been performed to exclude expanding intracranial lesions or tumors prior to initiating therapy
    Documentation Required

    Form Completion & Documentation Requirements

    Form completion and documentation requirements: The prescribing provider must complete the prior authorization form in full; incomplete forms will be returned. Documentation required for adult growth hormone deficiency includes biochemical evidence or other applicable testing supporting the diagnosis. For HIV-associated wasting (Serostim only), provide quantitative lean body mass measurement (DEXA or BIA) and documentation of involuntary weight loss >10% of baseline total body weight or body cell mass <30% for initial approval.

    • Prescribing provider must complete the form in full; incomplete requests will be returned. Fax to Prior Authorization of Benefits Center at 844-864-7860 (retail) or 888-209-7838 (medical injectable).
    • Documentation for adult growth hormone deficiency: biochemical evidence or other applicable testing supporting the diagnosis
    • For HIV-associated wasting (Serostim only): quantitative measurement of lean body mass via DEXA or BIA, and involuntary weight loss >10% of baseline total body weight OR body cell mass <30% for initial approval
    Body cell mass <30% for initial approval
    Indication noteApplies to diagnosis of HIV-associated wasting or cachexia (Serostim only)